Table 2.
Effects of S-diclofenac and diclofenac on 6-keto-PGF1α formation in paced isovolumic left rabbit heart preparations subjected to low-flow ischaemia and reperfusion
| Treatment |
6-keto-PGF1α (ng min−1 per g w.t.) |
||
|---|---|---|---|
| Pre-ischaemia | Reperfusiona | ||
| Vehicle | 3.15±0.53 | 13.22±1.42 | |
| S-diclofenac | 3 μM | 2.38±0.37 (24) | 10.81±1.05 (18) |
| S-diclofenac | 10 μM | 1.48±0.29 ** (53) | 7.13±0.94 * (46) |
| S-diclofenac | 30 μM | 0.51±0.12 *** (84) | 3.21±0.51 *** (76) |
| Diclofenac | 3 μM | 1.61±0.32 ** (49) | 8.33±1.04 * (37) |
| Diclofenac | 10 μM | 0.57±0.10 *** (82) | 3.59±0.18 *** (73) |
| Diclofenac | 30 μM | n.d. | 0.96±0.23 *** (93) |
Abbreviations: 6-keto-PGF1α, 6-keto-prostaglandin F1α; n.d., not detectable (detection limit 3 pg ml−1); S-diclofenac, 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(3H-1,2-dithiole-3-thione-5-yl)-phenyl ester; w.t., wet tissue.
Data are mean±s.e.mean of seven heart preparations per group. Values within parentheses show, percentage inhibition compared to vehicle-treated hearts. Drugs were infused for 20 min before flow rate reduction.
a
Data refer to the first 10 min of reperfusion.
*P<0.05, **P<0.01 and ***P<0.001 versus vehicle-treated hearts.